Related Experiment Video
Updated: Dec 23, 2025
04:29
Economical and Efficient Protocol for Isolating and Culturing Bone Marrow-derived Dendritic Cells from Mice
Published on: July 1, 2022
10.4K
Dendritic cells in hematological malignancies.
Domenico Galati1, Gaetano Corazzelli1, Rosaria De Filippi2
1Hematology-Oncology and Stem-Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Via Mariano Semmola 49, 80131 Naples, Italy.
Critical Reviews in Oncology/Hematology
|December 10, 2016
Summary
Dendritic cells (DCs), crucial immune cells, play a dual role in antitumor immunity by either stimulating or suppressing immune responses. This review highlights their significance in hematopoietic tumors.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Dendritic cells (DCs) are essential bone marrow-derived immune cells.
- DCs initiate adaptive and support innate immune responses.
- They act as potent antigen-presenting cells but can also induce immune tolerance.
Purpose of the Study:
- To review the dual role of dendritic cells in antitumor immunity.
- To highlight the regulatory significance of DCs in malignancies.
- To focus on the relevance of DCs in hematopoietic tumors.
Main Methods:
- Literature review of existing studies on dendritic cells and cancer.
- Analysis of the mechanisms by which DCs regulate immune responses.
- Synthesis of evidence on DC function in tumor pathogenesis and progression.
Main Results:
- DCs can stimulate anti-tumor T-cell responses by presenting tumor antigens.
- DCs can also promote tumor immune evasion through tolerogenic functions.
- The dual role of DCs may depend on their developmental stages and subsets.
Conclusions:
- Dendritic cells critically influence the balance between anti-tumor immunity and immune tolerance.
- Understanding DC subsets and functions is key to modulating anti-tumor responses.
- Bone marrow-derived DCs are central to the immune pathways regulating hematopoietic tumor progression.
